• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthFDA

The FDA Now Requires Stronger Warning Labels for Opioid Drugs

By
Reuters
Reuters
Down Arrow Button Icon
By
Reuters
Reuters
Down Arrow Button Icon
September 1, 2016, 10:36 AM ET
New England Towns Struggle With Opioid And Heroin Epidemic
Oxycodone pain pills prescribed for a patient with chronic pain lie on display on March 23, 2016 in Norwich, CT. Communities nationwide are struggling with the unprecidented opioid pain pill and heroin addiction epidemic. On March 15, the U.S. Centers for Disease Control (CDC), announced guidelines for doctors to reduce the amount of opioid painkillers prescribed, in an effort to curb the epidemic. The CDC estimates that most new heroin addicts first became hooked on prescription pain medication before graduating to heroin, which is stronger and cheaper.Photograph by John Moore—Getty Images

The U.S. Food and Drug Administration on Wednesday strengthened warnings about the danger of combining opioid painkillers or cough medicines containing opioids with benzodiazepines, a common class of sedatives.

The agency is requiring that black box warnings, the strongest available, be added to nearly 400 products, alerting doctors and patients that combining opioids and benzodiazepines can cause extreme sleepiness, slowed breathing, coma, and death.

The agency said the move is part of a broad action plan to reduce the number of deaths from opioid painkiller abuse.

“It is nothing short of a public health crisis when you see a substantial increase of avoidable overdose and death related to two widely used drug classes being taken together,” said FDA commissioner Robert Califf.

“We implore health care professionals to heed these new warnings,” he added.

Opioids include oxycodone, hydrocodone, fentanyl, and morphine, and are sold under such brand names as OxyContin, Percocet, Vicodin, and Actiq. Benzodiazepines include such drugs as alprazolam, clonazepam, and lorazepam, sold under the brands Xanax, Klonopin, and Ativan.

The move comes as prescriptions for both opioids and benzodiazepines has been increasing. Between 2004 and 2011 the number of patients who were prescribed an opioid and a benzodiazepine increased by 41 percent, the agency said, an increase of more than 2.5 million in opioid pain patients also receiving benzodiazepines.

The number of overdose deaths involving both classes of deaths nearly tripled over the same period, the FDA said.

Warnings about the interaction of both classes of drugs have been in existence for years, but are insufficient, the agency said. The current move strengthens them and “alerts all kinds of people who might otherwise have missed the message,” Califf said on a call with reporters.

The FDA’s action comes six months after city and state health directors, led by Baltimore City Health Commissioner Leana Wen, petitioned the FDA to require boxed warnings on the drugs.

Speaking on the call, Dr. Wen thanked the FDA for “acting so swiftly to our petition.”

Every day in the U.S., 44 people die as a result of prescription opioid overdoses. Wen said roughly one in three unintentional overdose deaths from opioids also involves benzodiazepines.

The reason, she said, is that prescribing opioids and benzodiazepines together has long been the medical norm. Over the years prescriptions of both have soared, resulting in the current epidemic.

About the Author
By Reuters
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.